Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, et al.; NETTER-1 Trial Investigators. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017. 376:125-135. PMCID:5895095

Menda Y, O’Dorisio TM, Howe JR, Schultz MK, Dillon J, Dick D, et al. Role of 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumors with an Unknown Primary Site. J Nuc Med 2017. 58: 1054-1057. PMCID:5493006

Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastasis.(NETLMs). Surgery 2019. 165:166-175. PMCID:6637412.

Dillon, J.S., Kulke, MH, Hörsch,D, Anthony, LB, Warner, RB, Bergsland, E, Welin, S, O’Dorisio, TM, Kunz, PM, McKee, C, Lapuerta, P, Pavel, M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase 3 Studies in Carcinoid Syndrome. Gastrointest Cancer. 2020 Mar 7. (Online ahead of print). PMID: 32146619

Pryma DA, Chin BB, Noto RB, Dillon, J.S., Perkins S, Solnes L, Kostakoglu L, Serafini AN, Pampaloni MH, Jensen J, Armor T, Lin T, White T, Stambler N, Apfel S, DiPippo V, Mahmood S, Wong V, Jimenez C.  Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.  J Nucl Med. 60(5): 623-630, 2019. PMID: 30291194.